Investor Presentation First Nine Months of 2023
6
Investor presentation
First nine months of 2023
Diabetes value market leadership reached 33.3%
60%
Novo Nordisk global diabetes value market shares
-Diabetes
-GLP-1
-Insulin
55.7%
54.3%
52.1%
49.9%
50%
44.6%
44.0%
44.2%
44.1%
40%
•
33.3%
31.5%
29.2%
29.9%
30%
0% T
2020
2021
2022
2023
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Note: Sales growth rates are at CER
Source: IQVIA MAT, Aug 2023 (Spot rate); Volume growth based on Moving Annual Total (MAT); Market values are based on the list prices
Diabetes value market leadership expansion
driven by the GLP-1 franchise
Diabetes care sales grew by 25% (CER) with global value
market share increase driven by market share gains in both
IO and NAO.
•
•
Global diabetes value market share increased by 1.8%-
points to 33.3%
Novo Nordisk continues to be the global market leader in
the GLP-1 segment with a 54.3% value market share
Estimated global GLP-1 share of total diabetes
prescriptions is ~6%
Novo NordiskⓇView entire presentation